CLAIMS

1. Formula (I) compounds:



I

in which:

Z may be selected from: H; saturated or unsaturated, straight or branched alkyl, consisting of from 1 to 7 carbon atoms, possibly substituted with alkoxy and halogens; aryl or heteroaryl, mono- or bicyclic, containing one or more heteroatoms selected from nitrogen, oxygen and sulphur, possibly substituted with halogens, NO_2, OH, alkyls and alkoxy, possibly substituted with halogens; arylalkyl or heteroarylalkyl, where the saturated or unsaturated alkyl residue consists of from 1 to 7 carbon atoms, mono- or bicyclic, containing one or more heteroatoms selected from nitrogen, oxygen and sulphur, possibly substituted with halogens, NO_2, OH, carboxy, alkyls and alkoxy, possibly substituted with halogens; or, together with W, may form a cycle, possibly containing one or more heteroatoms;

W may be equal to H or, together with Z, may form a cycle, possibly containing one or more heteroatoms;

n = 0-10;

Q may be selected from the Z groups listed above;

X and Y may be the same or different and may be selected from the Z groups listed above;

In addition, X may be a substituted amino-imino of the type:



where Z1 may be selected from the Z groups listed above;

or X may be an R-CO group and, with nitrogen, may form a group:



where R may be selected from the Z groups listed above or -OZ or -NZ;

when n = 0, the X-N-Y group may be replaced by an H;

and their pharmacologically acceptable salts, the racemic mixtures, the single enantiomers, stereoisomers and geometric isomers and tautomers

with the proviso that the formula (I) compound is not N-(4-aminobutyl)-N'-(γ,γ-dimethylallyl)guanidine methane sulphonate (ST2369) or N-(γ,γ-dimethylallyl)guanidine methane sulphonate (ST 2527).

2. Compounds according to claim 1, in which the Z group is a saturated or unsaturated alkyl that may contain from 1 to 7 carbon atoms.

3. Compounds according to claim 1, in which the Z group is an arylalkyl, with the aryl possibly substituted with one or more halogen atoms, in which preferably the alkyl bound to the aryl to form the arylalkyl group consists of a number of carbon atoms ranging from 1 to 5.

4. Compounds according to claim 1, in which X and Y are equal to hydrogen and n is equal to 4-7.

5. Compound according to claim 1, selected from the group consisting of:

i. N-(6-aminohexyl)-N'-(γ,γ-dimethylallyl)guanidine methane sulphonate (ST2370);

ii. N-(4-aminobutyl)-N'-(3-phenylpropyl)guanidine (ST2521);

iii. N-(4-aminobutyl)-N'-(4-fluorobenzyl)guanidine dichlorhydrate (ST2524);

iv. N-allyl-N'-(4-aminobutyl)guanidine dichlorhydrate (ST2525);

v. 1,4-bis-[N-(γ,γ-dimethylallyl)guanidino]-butane dimethane sulphonate (ST2526);

vi. N-(4-fluorofenil)-N'-(6-amminoesil)-)-4-metil-1-piperazinocarbossimmidammide (ST 2601);

vii. N-(4-fluorofenil)-N'-(6-amminoesil)-1-piperidinocarbossimmidammide (ST 2602);

viii. N-(4-fluorofenil)-N'-(4-amminobutil)-4-metil-1-piperazinocarbossimmidammide (ST2658);

ix. N-(γ,γ-dimetilallil)-N'-(5-amminopentil)guanidina metansolfonata (ST2574);

x. N-(γ,γ-dimetilallil)-N'-(7-amminoeptil)guanidina metansolfonata (ST2575).

6. Compounds according to claims 1-5 as medicines.

7. Pharmaceutical compositions containing at least one compound according to claims 1-5 in a mixture with one or more pharmaceutically acceptable vehicles and/or excipients.

8. Composition according to claim 7, in the form of tablets, rigid or soft capsules, powders, solutions, suspensions, syrups, solid forms for extempore liquid preparations, emulsions, liposomal preparations, forms for the controlled release of the active ingredient, tablets coated with appropriate layers, microencapsulated powders, complexes with cyclodextrin, depot forms, for example, subcutaneous ones, such as depot injections or implants.

9. Composition according to claim 8, which can be administered orally or parenterally.

10. Use of the compounds according to claims 1-5, for the preparation of a medicine with serum-glucose-lowering and serum-lipid-lowering activity.

11. Use of the compounds according to claims 1-5, for the preparation of a medicine for the prophylaxis and treatment of diabetes, particularly type 2 diabetes, and its complications, syndrome X, various forms of insulin resistance, hyperlipidaemias and obesity.

12. Use according to claim 10 or 11, in which the compound is selected from the group consisting of:

i. N-(6-aminohexyl)-N'-(γ,γ-dimethylallyl)guanidine methane sulphonate (ST2370);

ii. N-(4-aminobutyl)-N'-(3-phenylpropyl)guanidine (ST2521);

iii. N-(4-aminobutyl)-N'-(4-fluorobenzyl)guanidine dichlorhydrate (ST2524);

iv. N-allyl-N'-(4-aminobutyl)guanidine dichlorhydrate (ST2525);

v. 1,4-bis-[N-(γ,γ-dimethylallyl)guanidino]-butane dimethane sulphonate (ST2526);

vi. N-(4-aminobutyl)-N'-(γ,γ-dimethylallyl)guanidine methane sulphonate (ST2369);

vii. N-(γ,γ-dimethylallyl)guanidine methane sulphonate (ST2527);

viii. N-(4-fluorofenil)-N'-(6-amminoesil)-)-4-metil-1-piperazinocarbossimmidammide (ST 2601);

ix. N-(4-fluorofenil)-N'-(6-amminoesil)-1-piperidinocarbossimmidammide (ST 2602);

x. N-(4-fluorofenil)-N'-(4-amminobutil)-4-metil-1-piperazinocarbossimmidammide (ST2658);

xi. N-(γ,γ-dimetilallil)-N'-(5-amminopentil)guanidina metansolfonata (ST2574);

xii. N-(γ,γ-dimetilallil)-N'-(7-amminoeptil)guanidina metansolfonata (ST2575).